Global Allergy Immunotherapies Market Size, Share, Analysis and Forecasts, 2016-2020


Technavio Announces the Publication of its Research Report – Global Allergy Immunotherapies Market 2016-2020

Technavio recognizes the following companies as the key players in the global allergy immunotherapies market: ALK-Abello, Stallergenes, Merck Group, and Allergy Therapeutics.

Other Prominent Vendors in the market are: Adamis Pharmaceuticals, Aimmune Therapeutics, Anergis, ASIT biotech, Biomay, Circassia, DBV Technologies, Genentech, HAL Allergy, Laboratorios LETI, Mitsubishi Tanabe Pharma, Nycomed, Sementis, Shionogi, Torii, Tunitas Therapeutics, VentiRx Pharmaceuticals, and Verona Pharma.

Commenting on the report, an analyst from Technavio’s team said: “A trend propelling market growth is the advent of SPIRE. The SPIRE allergy immunotherapy is a novel method to treat allergies. This therapy uses the proprietary MicronJet system to maximize the immune response. MicronJet, a novel device approved in the US and the EU, provides patient friendly, consistent, and intradermal administration of drugs. Vendors are showing an interest in this patented novel synthetic pharmaceutical technology due to its ease of use and compatibility compared to the complex techniques of existing immunotherapies.”

Browse Detail Report With TOC @

According to the report, a key growth driver is the presence of high unmet medical needs. Though existing therapies are highly effective in relieving and controlling symptoms, the market still requires drugs that reduce inflammation and irreversible airway remodeling. In Europe, the US, and Japan, an estimated 39 million individuals are not in control of their respiratory-related allergies, as only a few drugs provide appropriate treatment; only about 4.5 million receive AIT. Globally, only 55% of all the allergic rhinitis cases have been diagnosed. In addition, allergic rhinitis and allergic asthma are chronic diseases...